Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A phase I study of an allogeneic cell vaccine (VACCIMEL) with GM-CSF in melanoma patients.

Journal of immunotherapy (Hagerstown, Md. : 1997)·2006
Same author

Neoadjuvant chemotherapy with gemcitabine and cisplatin in stage IIIA/B non-small cell lung cancer.

Investigational new drugs·2002
See all related articles

Related Experiment Video

Updated: Jun 7, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

Triple-negative breast cancer.

Reinaldo D Chacón1, María V Costanzo

  • 1Oncology Department, Instituto Alexander Fleming, Cramer 1180, zip code 1426 ANZ, Ciudad Autonoma de Buenos Aires, Argentina. rchacon@alexanderfleming.org

Breast Cancer Research : BCR
|November 6, 2010
PubMed
Summary
This summary is machine-generated.

Triple-negative (TN) breast cancer, characterized by a lack of hormone receptors and HER2, presents unique challenges. Despite chemosensitivity, TN tumors have a poor prognosis, necessitating novel therapeutic strategies.

Related Experiment Videos

Last Updated: Jun 7, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Triple-negative (TN) breast cancer lacks hormone receptors and HER2 overexpression, comprising ~15% of breast cancers.
  • TN tumors differ from basaloid tumors, exhibiting distinct molecular markers, higher histologic grade, and poorer prognosis.
  • These cancers disproportionately affect younger women, with a high early recurrence risk and a propensity for distant brain and visceral metastases.

Purpose of the Study:

  • To review the characteristics and therapeutic landscape of triple-negative breast cancer.
  • To highlight the challenges in managing TN breast cancer due to its aggressive nature and distinct metastatic patterns.
  • To explore current and emerging treatment strategies for TN breast cancer.

Main Methods:

  • Literature review of TN breast cancer classification, clinical behavior, and treatment options.
  • Analysis of prognostic factors and metastatic patterns specific to TN breast cancer.
  • Overview of established and investigational therapies, including chemotherapy, targeted agents, and novel drug classes.

Main Results:

  • TN breast cancer exhibits aggressive clinical behavior, including early recurrence and specific metastatic sites.
  • Standard chemotherapy (anthracyclines, taxanes) shows efficacy, but progression-free survival is often limited.
  • Combinations like ixabepilone-capecitabine, platinum agents, and antiangiogenic drugs show promise.
  • Poly-(ADP-ribose)-polymerase inhibitors demonstrate efficacy in BRCA-mutated TN tumors.
  • Ongoing trials investigate novel agents targeting EGFR, c-kit, kinase pathways, and mTOR.

Conclusions:

  • Triple-negative breast cancer requires distinct management strategies due to its aggressive biology and clinical behavior.
  • While chemotherapy remains a cornerstone, combination therapies and novel targeted agents, particularly PARP inhibitors for BRCA-mutated cases, offer improved outcomes.
  • Continued research into new drug classes is crucial for advancing treatment and improving survival for patients with TN breast cancer.